Valuation: Libra Infusions Limited

Market Cap 1.53B 189B 1.34B 1.24B 1.16B 2.18B 145B 2.22B 14.9B 5.76B 71.5B 5.76B 5.63B 248B P/E 2016
131x
P/E 2017 107x
Enterprise Value 2.43B 298B 2.13B 1.96B 1.84B 3.44B 229B 3.52B 23.58B 9.13B 113B 9.12B 8.92B 392B EV / Sales 2016
6.88x
EV / Sales 2017 6.34x
Free-Float
99%
Yield 2016
0.41%
Yield 2017 0.57%
1 day+0.45%
1 week+0.80%
Current month+2.72%
1 month+2.72%
3 months-3.38%
6 months+2.55%
Current year+1.29%
1 week 630
Extreme 630
646.8
1 month 625.4
Extreme 625.4
685
Current year 547.1
Extreme 547.1
739
1 year 547.1
Extreme 547.1
850
3 years 445.73
Extreme 445.7333
1,146.67
5 years 350
Extreme 350
1,146.67
10 years 238.33
Extreme 238.3333
1,146.67
Manager TitleAgeSince
Chief Executive Officer - 1976-02-01
Director of Finance/CFO - -
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member - 2011-06-20
Chairman - 2013-02-12
Director/Board Member - 2011-06-20
Change 5-day change 1-year change 3-year change Capi.($)
+0.45%+0.80%-20.61%+43.12% 11.77M
+7.13%+9.97%+55.80%+160.09% 1,077B
+3.99%+11.50%+67.09%+55.96% 613B
+4.20%+17.03%+38.97%+91.06% 448B
+0.99%+4.85%+28.17%+23.89% 332B
+1.82%+8.19%+40.04%+27.95% 293B
+0.22%+6.75%+31.30%+42.34% 286B
+0.73%+8.53%-27.33%-39.55% 215B
+1.56%+6.14%+29.30%+60.97% 193B
+3.26%+3.33%+15.55%+68.24% 159B
Average +2.43%+7.26%+25.83%+53.41% 361.61B
Weighted average by Cap. +3.85%+8.93%+41.75%+80.17%

Financials

2016 2017
Net sales 238M 29.28B 209M 192M 180M 338M 22.46B 345M 2.31B 895M 11.1B 894M 875M 38.5B 244M 30.03B 214M 197M 185M 347M 23.04B 354M 2.37B 918M 11.39B 917M 897M 39.49B
Net income 5.82M 716M 5.1M 4.7M 4.4M 8.26M 549M 8.43M 56.54M 21.88M 271M 21.86M 21.38M 941M 6.09M 748M 5.34M 4.92M 4.6M 8.63M 574M 8.81M 59.11M 22.87M 284M 22.85M 22.35M 984M
Net Debt 880M 108B 771M 711M 666M 1.25B 82.97B 1.27B 8.54B 3.31B 41.01B 3.3B 3.23B 142B 894M 110B 784M 723M 677M 1.27B 84.34B 1.29B 8.69B 3.36B 41.68B 3.36B 3.28B 145B
Logo Libra Infusions Limited
Libra Infusions Ltd is a Bangladesh-based company engaged in the manufacturing of Intravenous (I.V.) fluid. The Company's products include LIBOTT, LIBOTT-10, LIBOTT-25, LIBOTT-S, LIBOTT-S JR, NORMASOL, BABY SALINE, DIASOL, HARTSOL, LIBRAZOL, LIBRACIN, LIBOTT-M, LIBRACIN-400, and LIBRET. Its products are used in medical situations involving diarrheal disease, surgical operation, loss of blood, weakness and hospitalization in general. LIBOTT is used for rehydration in a time of water deficit, general weakness and post-surgical intervention. LIBOTT-10 is used for the treatment of jaundice, general weakness, eclampsia and pre-eclampsia. LIBOTT-25 is used in the emergency treatment of severe hypoglycemia. LIBOTT-S is used for rehydration during general weakness, water deficiency along with sodium, diuresis, intoxication and post-surgical intervention. LIBOTT-S JR fulfills the water deficit along with low deficiency of sodium chloride and supplies energy for growing children.
Employees
699
Date Price Change Volume
26-06-25 BDT 642.40 +0.45% 4,406
26-06-24 BDT 639.50 +0.82% 4,590
26-06-23 BDT 634.30 +0.22% 2,699
26-06-22 BDT 632.90 -0.92% 9,191
26-06-21 BDT 638.80 +0.24% 3,818
  1. Stock Market
  2. Stocks
  3. LIBRAINFU Stock